Literature DB >> 24556086

Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D).

H F A Vasen1, Z Ghorbanoghli, F Bourdeaut, O Cabaret, O Caron, A Duval, N Entz-Werle, Y Goldberg, D Ilencikova, C P Kratz, N Lavoine, J Loeffen, F H Menko, M Muleris, G Sebille, C Colas, B Burkhardt, L Brugieres, K Wimmer.   

Abstract

Lynch syndrome (LS) is an autosomal dominant disorder caused by a defect in one of the DNA mismatch repair genes: MLH1, MSH2, MSH6 and PMS2. In the last 15 years, an increasing number of patients have been described with biallelic mismatch repair gene mutations causing a syndrome referred to as 'constitutional mismatch repair-deficiency' (CMMR-D). The spectrum of cancers observed in this syndrome differs from that found in LS, as about half develop brain tumours, around half develop digestive tract cancers and a third develop haematological malignancies. Brain tumours and haematological malignancies are mainly diagnosed in the first decade of life, and colorectal cancer (CRC) and small bowel cancer in the second and third decades of life. Surveillance for CRC in patients with LS is very effective. Therefore, an important question is whether surveillance for the most common CMMR-D-associated cancers will also be effective. Recently, a new European consortium was established with the aim of improving care for patients with CMMR-D. At a workshop of this group held in Paris in June 2013, one of the issues addressed was the development of surveillance guidelines. In 1968, criteria were proposed by WHO that should be met prior to the implementation of screening programmes. These criteria were used to assess surveillance in CMMR-D. The evaluation showed that surveillance for CRC is the only part of the programme that largely complies with the WHO criteria. The values of all other suggested screening protocols are unknown. In particular, it is questionable whether surveillance for haematological malignancies improves the already favourable outcome for patients with these tumours. Based on the available knowledge and the discussions at the workshop, the European consortium proposed a surveillance protocol. Prospective collection of all results of the surveillance is needed to evaluate the effectiveness of the programme.

Entities:  

Keywords:  CMMR-D; Constitutional mismatch repair deficiency; Guidelines; Surveillance; Tumour spectrum

Mesh:

Year:  2014        PMID: 24556086     DOI: 10.1136/jmedgenet-2013-102238

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  53 in total

1.  Successful matched sibling cord blood transplant for ALL in a child with constitutional mismatch repair deficiency syndrome.

Authors:  J A Heath; M Campbell; K Tiedemann; P A Downie
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

2.  Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  A Kerpel; M Yalon; M Soudack; J Chiang; A Gajjar; K E Nichols; Z Patay; S Shrot; C Hoffmann
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

3.  Diagnostic challenges in a child with early onset desmoplastic medulloblastoma and homozygous variants in MSH2 and MSH6.

Authors:  Julia Taeubner; Katharina Wimmer; Martine Muleris; Olivier Lascols; Chrystelle Colas; Christine Fauth; Triantafyllia Brozou; Joerg Felsberg; Jasmin Riemer; Michael Gombert; Sebastian Ginzel; Jessica I Hoell; Arndt Borkhardt; Michaela Kuhlen
Journal:  Eur J Hum Genet       Date:  2018-01-04       Impact factor: 4.246

4.  Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation.

Authors:  Nisreen Amayiri; Maysa Al-Hussaini; Maisa Swaidan; Imad Jaradat; Monther Qandeel; Uri Tabori; Cynthia Hawkins; Awni Musharbash; Khulood Alsaad; Eric Bouffet
Journal:  Childs Nerv Syst       Date:  2015-08-21       Impact factor: 1.475

Review 5.  Clinical management of hereditary colorectal cancer syndromes.

Authors:  Hans F A Vasen; Ian Tomlinson; Antoni Castells
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-13       Impact factor: 46.802

6.  PMS2 inactivation by a complex rearrangement involving an HERV retroelement and the inverted 100-kb duplicon on 7p22.1.

Authors:  Julia Vogt; Annekatrin Wernstedt; Tim Ripperger; Brigitte Pabst; Johannes Zschocke; Christian Kratz; Katharina Wimmer
Journal:  Eur J Hum Genet       Date:  2016-06-22       Impact factor: 4.246

7.  Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Authors:  Claudia Maletzki; Yvonne Saara Gladbach; Mohamed Hamed; Georg Fuellen; Marie-Luise Semmler; Jan Stenzel; Michael Linnebacher
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

Review 8.  Translational Research in Familial Colorectal Cancer Syndromes.

Authors:  Molly M Ford
Journal:  Clin Colon Rectal Surg       Date:  2018-05-01

Review 9.  Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Authors:  Erika K S M Leenders; Harm Westdorp; Roger J Brüggemann; Jan Loeffen; Christian Kratz; John Burn; Nicoline Hoogerbrugge; Marjolijn C J Jongmans
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

Review 10.  Management of familial cancer: sequencing, surveillance and society.

Authors:  Nardin Samuel; Anita Villani; Conrad V Fernandez; David Malkin
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.